

AMENDMENT

In the Specification

Page 5, line 21, after "analog(s)." insert: "As used herein, "lysine analog" means a compound that can serve as an amino donor for a DAPA amino transferase, e.g., (S)-2-aminoethyl-L-cysteine."

Page 7, line 8, after "donor." insert "As used herein, "SAM analog" means a compound that is structurally similar to SAM that can serve as an amino donor for a DAPA amino transferase."

Page 25, line 26, insert "BI 282 55574" inside the box.

Remarks

This is in response to the February 1, 1999 Office Action issued in the above captioned application. Applicants acknowledge that there are no prior art rejections currently outstanding.

35 USC 112, second paragraph

The Examiner rejected claims 1, 5, 6, 9, and 15-18 as being indefinite under 35 USC §112, second paragraph. Specifically, the Examiner takes exception to the language "lysine analog" used in the rejected claims.

Applicants respectfully submit that the term "lysine analog" as used in claim 14 satisfies the statutory mandate of 35 U.S.C. § 112, second paragraph. For additional clarity, however, Applicants have amended the specification at page 5 to set forth the definition noted by the Examiner appearing at p. 7, lines 14-16. Applicants submit that no new matter has been added by the above amendment. In particular, in addition that definition, one of skill in the art would